Emerald Advisers LLC Increases Holdings in LivaNova PLC (NASDAQ:LIVN)

Emerald Advisers LLC increased its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 8.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 752,540 shares of the company's stock after purchasing an additional 57,035 shares during the period. LivaNova makes up 1.4% of Emerald Advisers LLC's investment portfolio, making the stock its 18th largest holding. Emerald Advisers LLC owned 1.39% of LivaNova worth $34,850,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LIVN. Vanguard Group Inc. grew its position in LivaNova by 12.7% during the fourth quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock valued at $108,823,000 after buying an additional 265,291 shares during the period. Fox Run Management L.L.C. raised its stake in LivaNova by 183.7% during the 4th quarter. Fox Run Management L.L.C. now owns 19,843 shares of the company's stock valued at $919,000 after purchasing an additional 12,848 shares during the period. KLP Kapitalforvaltning AS bought a new position in LivaNova in the 4th quarter worth approximately $509,000. American Century Companies Inc. grew its holdings in LivaNova by 32.9% during the 4th quarter. American Century Companies Inc. now owns 150,760 shares of the company's stock valued at $6,982,000 after buying an additional 37,306 shares in the last quarter. Finally, Xponance Inc. raised its position in shares of LivaNova by 6.1% during the fourth quarter. Xponance Inc. now owns 7,762 shares of the company's stock valued at $359,000 after buying an additional 445 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on LIVN. Needham & Company LLC restated a "buy" rating and set a $64.00 target price on shares of LivaNova in a research report on Monday, March 17th. Wolfe Research cut LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. StockNews.com upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a report on Tuesday. The Goldman Sachs Group lowered their price target on LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Finally, Stifel Nicolaus cut their price objective on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $61.17.

LivaNova Trading Down 0.7 %

LivaNova stock traded down $0.28 during mid-day trading on Thursday, hitting $39.62. The company's stock had a trading volume of 487,663 shares, compared to its average volume of 593,402. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The company has a 50 day moving average of $44.69 and a 200-day moving average of $48.52. LivaNova PLC has a one year low of $36.85 and a one year high of $64.48. The stock has a market cap of $2.15 billion, a PE ratio of 94.33 and a beta of 1.10.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.